Cytek Biosciences (CTKB) Cash from Investing Activities (2020 - 2026)

Cytek Biosciences' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$27.1 million for Q1 2026.

• Quarterly Cash from Investing Activities fell 386.49% year-over-year to -$27.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$26.4 million (up 61.02% YoY) and the FY2025 annual result came in at $10.1 million, up 112.19% from the prior year.
• Cash from Investing Activities was -$27.1 million for Q1 2026 at Cytek Biosciences, down from -$1.8 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $43.1 million in Q3 2023 and bottomed at -$168.9 million in Q1 2023.
• A 5-year average of -$14.7 million and a median of -$1.8 million in 2025 frame the typical range for Cash from Investing Activities.
• Peak annual rise in Cash from Investing Activities reached 3849.91% in 2023, while the deepest fall reached 21550.51% in 2023.
• Cytek Biosciences' Cash from Investing Activities stood at -$51.1 million in 2022, then soared by 156.92% to $29.1 million in 2023, then sank by 318.24% to -$63.4 million in 2024, then jumped by 97.1% to -$1.8 million in 2025, then plunged by 1370.09% to -$27.1 million in 2026.
• Business Quant data shows CTKB's Cash from Investing Activities at -$27.1 million in Q1 2026, -$1.8 million in Q4 2025, and $18.9 million in Q3 2025.